Matrix-M Malaria Vaccine Meets WHO Objectives

Creators of the AstraZeneca Covid-19 vaccine from the University of Oxford have developed a new inoculation, the R21/Matrix-M, against Malaria. Following a trial of three doses on children from West Africa, the vaccine proved to have 77% effectiveness the period of a year, exceeding the WHO’s 75% objective.

Just shy of 410 kids aged between 5 and 17 months old got a fourth booster with a high or low volume of Novavax’s Matrix-M, designed to enhance the immune response to the foreign body, in a supplemently trial to one involving 450 participants.

For participants who received the lower volume of Matrix-M, the rate of effectiveness was 70%, while in the high volume group experienced a rate of 80%.

Irish vaccinologist, Professor Adrian Hill, explained “we are delighted to find that a standard four-dose immunisation regime can now, for the first time, reach the high efficacy level over two years that has been an aspirational target for malaria vaccines for so many years.”

British epidemiologist Professor Azra Ghani commented that these results are “particularly encouraging from a scientific perspective.” Referring to both “the demonstration that antibody titres can be restored through boosting with this vaccine, and that the antibody titres correlate with protection against clinical disease.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.